Canberra man John uses cannabis daily to help cope with his post-traumatic stress disorder (PTSD).
When the personal use of cannabis was decriminalised in the ACT in January 2020, Mary couldn't wait to start growing the plant that she uses to treat her chronic depression and arthritis.
"It was time to take our power back and grow for ourselves and produce our own medicine at a lower cost in a healthier way," she said.
If you or anyone you know needs help:
He said while it was helpful the ACT's recreational laws were providing some medicinal benefit to people, it was ultimately a Commonwealth responsibility to make further changes to medicinal cannabis laws.
Mr Pettersson more recently tabled a new bill calling for the decriminalisation of small amounts of illicit drugs like ice and heroin, which a special inquiry has since recommended should be passed into ACT law.
Canberrans using cannabis to cope with trauma
Despite the risks, Mary said returning to conventional medication to treat her chronic conditions was not an option in her mind.
"Those handcuffs have been released and, as such, now I can put them up in the air as an advocate and say 'hey look at all the positive things about this plant'.
Dr. Karyn Grossman commented: “I am thrilled to be a part of the new Zelira Dermatology and to have teamed up with Zelira to create Zylorma ™ and the RAF FIVE ™ skin care line. Zelira is already known as a leader in cannabinoid research and development for the medical cannabis market, so when they offered me the opportunity to use my medical expertise alongside their ground-breaking scientific formulations to create a truly new and unique solution for acne, I couldn’t pass it up. In my medical practice I’ve spent many years treating patients suffering from acne and have seen firsthand their struggle to find effective treatments, so I am so excited to see the results from our ongoing patient study and the marked improvement after using the RAF FIVE ™ products. I believe that science has just started to skim the surface of the skin-healing properties of cannabinoids; RAF FIVE ™ is only the beginning.”
Securities Disclosure: I, Ronelle Richards, hold no direct investment interest in any company mentioned in this article.
In another show of support for the drug, the NSW government has established the Centre for Medicinal Cannabis Research and Innovation to educate the community and monitor clinical trials.
Medicinal cannabis can be prescribed by any doctor for a patient with any condition if they believe it is clinically appropriate. Victoria was the first state to legalise medical marijuana use, and young children suffering from epilepsy were the first to gain access.
The Future of Tech in Australia
The situation gets more complex at the state and territory level, as each area of Australia has different rules and regulations that must be followed. Read on for a breakdown of the laws for medicinal and recreational cannabis in Australia’s six states and two territories.
Approval under South Australian Controlled Substances legislation is also often required, although there are exemptions for elderly and terminal patients.
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF) is a leading global biopharmaceutical company manufacturing and marketing cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world’s largest and fastest growing markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.
Guide to Cannabis in Australia: Australian Capital Territory
Medicinal cannabis is available for patients with a number of conditions and also on a case-by-case basis. Doctors must have approval from the ACT chief health officer and the TGA to prescribe.
Zelira Therapeutics CEO and Managing Director, Dr. Oludare Odumosu , commented, “I am excited to announce the launch of Zelira’s Dermatology subsidiary and the RAF FIVE ™ acne treatment line of skincare products. Dr. Grossman’s reputation and experience in the cosmetic dermatology industry, combined with Zelira’s peerless position in cannabinoid science, is the perfect combination. We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the US$11 billion acne treatment market where there is a high level of dissatisfaction with existing products and unmet needs. Zelira is staking a claim in the cannabinoid-based, over-the-counter skincare product market with our differentiated dermatology.”